July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved their Dupixent injection for the treatment of adult patients ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Sanofi logo at the company's headquarters during the annual results news conference in Paris (Reuters) -Sanofi won ...
Sanofi and Regeneron Announce FDA Approval of Dupixent ® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis - Dupixent will be available later this ...
WASHINGTON -- The FDA approved the biologic drug dupilumab (Dupixent) for adults with moderate to severe atopic dermatitis, or eczema, that is not controlled with topical treatments or who need a ...
Rivals are closing in on Sanofi and Regeneron’s Dupixent. With AbbVie’s Rinvoq having already bested Dupixent in atopic dermatitis, Pfizer has now chalked up its own efficacy win over the blockbuster ...
Sanofi, Inc.SNY and partner Regeneron Pharmaceuticals, Inc. REGN announced that a phase II study evaluating its injection Dupixent for the treatment of adults with active moderate-to-severe ...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi have announced that the European Commission has granted approval for Dupixent (dupilumab) to be utilized in the treatment of eosinophilic ...
Sanofi looks compelling with strong fundamentals and a robust pipeline. Click for this updated look at SNY stock and why I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results